ZNTL revenueQ4 2025$0
- Quarter YoY
- -100.0%
- FY YoY
- -100.0%
ZNTL revenue was $0 in fiscal Q4 2025 (ended Dec 31, 2025), down 100.0% from a year earlier. For the full fiscal 2025 it was $0, down 100.0% from fiscal 2024.
Zentalis Pharmaceuticals Inc. (ZNTL) financials
For fiscal 2025 (ended Dec 31, 2025), Zentalis Pharmaceuticals Inc. reported $0 of revenue and -$137.06M of net income.
- Revenue, FY2025
- $0
- Revenue growth, YoY
- -100.0%
- Net income, FY2025
- -$137.06M
- Free cash flow, FY2025
- -$125.25M
- EPS, diluted, FY2025
- -$1.91
- Cash
- $24.03M
- Market cap
- $170.4M
FY2022FY2025
FY2019FY2025
FY2019FY2025
ZNTL revenue and earnings growth
ZNTL net incomeQ3 2026-$28.82M
ZNTL net income was -$28.82M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$26.69M a year earlier. For the full fiscal 2025 it was -$137.06M, compared with -$165.84M in fiscal 2024.
ZNTL EPSQ3 2026-$0.34
ZNTL diluted EPS was -$0.34 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.37 a year earlier. For the full fiscal 2025 it was -$1.91, compared with -$2.33 in fiscal 2024.
ZNTL free cash flowQ3 2026-$32.71M
ZNTL free cash flow was -$32.71M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$26.96M a year earlier. For the full fiscal 2025 it was -$125.25M, compared with -$171.08M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $67.42M | $0 | $0 | - | - | - |
| Research and development | $107.30M | $167.77M | $189.59M | $172.73M | $175.60M | $84.90M | $38.39M |
| Selling, general and admin | $37.72M | $87.11M | $64.35M | $54.55M | $40.94M | $33.89M | $8.46M |
| Operating income | -$152.81M | -$191.19M | -$299.51M | -$227.29M | -$216.54M | -$118.79M | -$46.84M |
| Pre-tax income | -$136.62M | -$165.69M | -$292.91M | -$237.58M | -$166.39M | -$118.10M | -$46.36M |
| Income tax | $442.0K | $177.0K | -$601.0K | -$469.0K | -$297.0K | $444.0K | $15.0K |
| Net income | -$137.06M | -$165.84M | -$292.19M | -$236.81M | -$158.72M | -$117.84M | -$45.66M |
| EPS, basic | -$1.91 | -$2.33 | -$4.47 | -$4.48 | -$3.72 | -$4.19 | - |
| EPS, diluted | -$1.91 | -$2.33 | -$4.47 | -$4.48 | -$3.72 | -$4.19 | -$8.16 |
| Diluted shares | 71.9M | 71.1M | 65.4M | 52.9M | 42.7M | 28.1M | 5.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $35.99M | $36.53M | $28.04M | $45.70M | $62.58M | $56.27M | $67.49M |
| Receivables | $0 | $5.00M | $0 | - | $4.0K | $417.0K | $140.0K |
| Current assets | $253.19M | $386.07M | $496.72M | $451.93M | $350.77M | $345.10M | $68.89M |
| Goodwill | - | $0 | $3.74M | $3.74M | $3.74M | $3.74M | $3.74M |
| Total assets | $288.97M | $430.34M | $551.69M | $539.31M | $454.51M | $365.56M | $87.48M |
| Current liabilities | $36.56M | $52.73M | $69.37M | $56.65M | $43.94M | $28.60M | $14.90M |
| Total liabilities | $72.76M | $93.15M | $114.30M | $105.29M | $90.03M | $32.18M | $19.06M |
| Shareholders' equity | $216.20M | $337.19M | $437.39M | $434.02M | $364.48M | $333.38M | -$73.28M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$125.25M | -$170.86M | -$207.82M | -$163.75M | -$154.09M | -$86.83M | -$39.14M |
| Capital expenditures | $0 | $221.0K | $583.0K | $2.55M | $6.11M | $758.0K | $352.0K |
| Free cash flow | -$125.25M | -$171.08M | -$208.41M | -$166.30M | -$160.20M | -$87.58M | -$39.49M |
| Investing cash flow | $131.62M | $176.56M | -$44.46M | -$114.18M | -$18.11M | -$284.83M | -$352.0K |
| Financing cash flow | -$4.28M | $108.0K | $237.30M | $261.04M | $178.52M | $360.44M | $81.83M |
| Share repurchases | $9.98M | $0 | $0 | - | - | - | - |
| Stock-based compensation | $20.72M | $67.27M | $54.82M | $46.84M | $35.74M | $23.15M | $617.0K |
| Depreciation and amortization | $739.0K | $1.29M | $1.39M | $1.43M | $544.0K | $160.0K | $111.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | - | - | - | - | - | - |
| Operating margin | - | -283.6% | - | - | - | - | - |
| Net margin | - | -246.0% | - | - | - | - | - |
| Free cash flow margin | - | -253.7% | - | - | - | - | - |
| Return on equity | -63.4% | -49.2% | -66.8% | -54.6% | -43.5% | -35.3% | - |
| Return on assets | -47.4% | -38.5% | -53.0% | -43.9% | -34.9% | -32.2% | -52.2% |
| Current ratio | 6.93 | 7.32 | 7.16 | 7.98 | 7.98 | 12.07 | 4.62 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $0 | $0 | $0 | $0 | $26.86M | $0 | $0 | $40.56M | $0 |
| Research and development | $22.33M | $35.16M | $28.72M | $29.49M | $22.95M | $27.61M | $27.25M | $32.97M | $36.82M | $48.39M | $49.59M | $51.56M |
| Selling, general and admin | $8.82M | $9.23M | $9.14M | $7.91M | $10.78M | $8.45M | $10.58M | $40.01M | $14.61M | $16.76M | $15.74M | $16.36M |
| Operating income | -$31.15M | -$44.39M | -$37.85M | -$37.39M | -$33.73M | -$36.06M | -$45.62M | -$49.85M | -$51.43M | -$65.15M | -$24.77M | -$67.92M |
| Pre-tax income | -$28.70M | -$42.15M | -$35.23M | -$34.77M | -$26.69M | -$26.87M | -$48.28M | -$47.68M | -$40.19M | -$88.01M | $10.18M | -$77.09M |
| Income tax | $118.0K | $138.0K | $120.0K | $442.0K | $0 | $0 | $0 | -$205.0K | -$27.0K | $266.0K | $143.0K | -$135.0K |
| Net income | -$28.82M | -$42.29M | -$35.35M | -$35.22M | -$26.69M | -$26.87M | -$48.28M | -$47.47M | -$40.16M | -$88.28M | $10.07M | -$60.92M |
| EPS, basic | -$0.34 | -$0.59 | -$0.50 | -$0.50 | -$0.37 | -$0.37 | -$0.67 | -$0.67 | -$0.56 | -$1.24 | $0.14 | -$0.76 |
| EPS, diluted | -$0.34 | -$0.59 | -$0.50 | -$0.50 | -$0.37 | -$0.37 | -$0.67 | -$0.67 | -$0.56 | -$1.24 | $0.14 | -$0.76 |
| Diluted shares | 84.6M | 71.3M | 70.3M | - | 72.1M | 72.0M | 71.7M | - | 71.1M | 71.0M | 71.2M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $24.03M | $24.78M | $31.93M | $35.99M | $39.07M | $37.60M | $41.93M | $36.53M | $41.32M | $36.98M | $37.62M | $28.04M |
| Receivables | - | - | - | $0 | $0 | $0 | $0 | $5.00M | - | - | - | $0 |
| Current assets | $237.27M | $181.28M | $218.10M | $253.19M | $288.30M | $311.60M | $342.88M | $386.07M | $400.27M | $439.62M | $503.81M | $496.72M |
| Goodwill | - | - | - | - | - | - | - | $0 | $3.74M | $3.74M | $3.74M | $3.74M |
| Total assets | $270.19M | $215.33M | $253.07M | $288.97M | $327.25M | $351.71M | $384.02M | $430.34M | $450.66M | $491.68M | $557.48M | $551.69M |
| Current liabilities | $32.36M | $37.63M | $35.24M | $36.56M | $37.17M | $39.02M | $49.43M | $52.73M | $54.88M | $66.69M | $54.80M | $69.37M |
| Total liabilities | $65.31M | $71.68M | $70.39M | $72.76M | $74.38M | $77.21M | $88.64M | $93.15M | $96.33M | $109.10M | $98.71M | $114.30M |
| Shareholders' equity | $204.89M | $143.65M | $182.68M | $216.20M | $252.87M | $274.50M | $295.38M | $337.19M | $354.33M | $382.58M | $458.77M | $437.39M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.71M | -$37.24M | -$32.96M | -$30.94M | -$26.96M | -$34.71M | -$32.64M | -$39.70M | -$44.05M | -$35.14M | -$51.97M | -$40.60M |
| Capital expenditures | $0 | $0 | $34.0K | $0 | $0 | $0 | $0 | $0 | $0 | $181.0K | $40.0K | $173.0K |
| Free cash flow | -$32.71M | -$37.24M | -$32.99M | -$30.94M | -$26.96M | -$34.71M | -$32.64M | -$39.70M | -$44.05M | -$35.32M | -$52.01M | -$40.77M |
| Investing cash flow | -$55.31M | $30.02M | $30.01M | $32.45M | $28.32M | $30.38M | $40.48M | $32.28M | $48.24M | $34.49M | $61.55M | -$42.06M |
| Financing cash flow | $87.26M | $65.0K | -$1.12M | -$4.59M | $115.0K | $0 | $189.0K | $0 | $92.0K | $9.0K | $7.0K | $0 |
| Stock-based compensation | $3.21M | $3.21M | $3.20M | $3.12M | $4.83M | $6.29M | $6.49M | $31.36M | $10.36M | $12.71M | $12.83M | $13.88M |
| Depreciation and amortization | $152.0K | $152.0K | $151.0K | $157.0K | $160.0K | $160.0K | $262.0K | $317.0K | $321.0K | $327.0K | $324.0K | $337.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | -100.0% | - | - | -100.0% | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | -185.6% | - | - | -61.1% | - |
| Net margin | - | - | - | - | - | - | - | -176.7% | - | - | 24.8% | - |
| Free cash flow margin | - | - | - | - | - | - | - | -147.8% | - | - | -128.2% | - |
| Current ratio | 7.33 | 4.82 | 6.19 | 6.93 | 7.76 | 7.99 | 6.94 | 7.32 | 7.29 | 6.59 | 9.19 | 7.16 |
Source: XBRL data Zentalis Pharmaceuticals Inc. files with the SEC, latest filing dated Nov 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ZNTL peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ZNTL | $0 | -100.0% | -$137.06M | - | $170.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
ZNTL FAQ
8 questionsWhat is ZNTL revenue?
Zentalis Pharmaceuticals Inc. (ZNTL) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is ZNTL profitable?
No. Zentalis Pharmaceuticals Inc. reported a net loss of $137.06M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ZNTL have?
Zentalis Pharmaceuticals Inc. reported $24.03M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is ZNTL revenue growing?
Zentalis Pharmaceuticals Inc.'s revenue changed -100.0% in fiscal 2025, to $0.What is ZNTL free cash flow?
Zentalis Pharmaceuticals Inc. generated -$125.25M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$125.25M less capital expenditures.What is ZNTL earnings per share?
Diluted earnings per share were -$1.91 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did ZNTL last report financial results?
The latest statements here come from Zentalis Pharmaceuticals Inc.'s 10-Q filed on Nov 9, 2026, covering the period ended Sep 30, 2026.Where does this ZNTL financial data come from?
Quantisnow builds these statements from the structured XBRL data Zentalis Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.